Positive results from two Phase III studies of Tradjenta (Boehringer/Eli Lilly) in Type 2 Diabetes patients

Results from two Phase III trials provide additional data evaluating the efficacy and safety of Tradjenta (linagliptin), from Boehringer/Eli Lilly, in adults with Type 2 Diabetes. Interim results of the first study showed that adding Tradjenta to a background of basal insulin � alone or in combination with metformin and/or pioglitazone � demonstrated a reduction in hemoglobin A1c of 0.65 percent from a baseline at 24 weeks versus adding placebo. In a second study, Tradjenta showed a 0.64 percent reduction in A1C at 24 weeks in elderly patients (mean age 74.9 years) insufficiently controlled despite previous treatment with metformin and/or sulfonylurea and/or insulin therapy. Hypoglycemia occurred in 24.1 percent of patients on linagliptin versus 16.5 percent of patients on placebo. Results were presented at the American Diabetes Association's 72nd Scientific Sessions.